

Special Issue

Foot and Mouth Disease Virus Vaccines Developments

Message from the Guest Editors

Foot-and-mouth disease virus (FMDV) is a highly contagious viral infection of cloven-hoofed animals. FMDV outbreaks cause significant and devastating economic impacts worldwide. The most effective and widely accepted way to respond to outbreaks is through the use of chemically inactivated vaccination of domestic livestock. However, these inactivated vaccines are slow-acting and do not always permit a distinction between infected and vaccinated animals. Therefore, it is essential to develop new rapid vaccines and control strategies that could confer early protection and rapidly stop disease spread. This Special Issue will cover the FMDV determinant of replication and pathogenesis and how this information facilitates next-generation FMDV vaccine and biotherapeutic developments. We particularly encourage the submission of manuscripts focused on improved control strategies addressing important gaps in the current inactivated FMDV vaccine including, but not limited to, duration of immunity, cross-reactivity, correlates of protection, early protection, antigen load, immunization responses, and safer marker vaccines.

Guest Editors

Dr. Katherine Pflaum

Foreign Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, Plum Island Animal Disease Center, Greenport, NY 11944, USA

Dr. Wilna Vosloo

Australian Centre for Disease Preparedness, CSIRO-Health & Biosecurity, 5 Portarlington Road, Geelong, VIC 3220, Australia

Deadline for manuscript submissions

closed (16 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/147306

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).